NMR metabolomics improves prediction of cardiometabolic diseases

In a preprint study of 54,933 participants from an integrated US healthcare system, researchers evaluated nuclear magnetic resonance metabolomics to stratify risk across nine cardiovascular-kidney-metabolic endpoints. The team profiled 250 nuclear magnetic resonance biomarkers linked to longitudinal electronic health records. Adding these biomarkers to standard-of-care predictors improved discrimination for nearly all endpoints. The largest gains occurred for type 2 diabetes, chronic kidney disease, and metabolic dysfunction-associated steatotic liver disease. Beyond initial onset, metabolomic profiling improved predictions of disease-specific complications and cross-organ outcomes. These predictive gains persisted across demographic, anthropometric, and genetic-risk strata. The largest benefits appeared where standard-of-care models were weakest, while preserving calibration and improving high-risk patient enrichment.